$1250 | Single User
$1800 | Site License
$2500 | Global License

Abuse Deterrents: Pipeline Analytics, H1 2020
[Lowest Price Guaranteed: $1,250]

Published by Gervano R A: 26 Mar 2019 | 270539 | In Stock
Related Topics: Drug

Introduction

GervanoRA’s Pipeline Drug Analytics Report "Abuse Deterrents Pipeline Drugs: Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H2 2020" provides a detailed overview on Abuse Deterrents Competitive Space. Report provides deep insights on pipeline analytics outlook, drivers, restraints and unmet needs of Abuse Deterrents pipeline drugs, Pipeline Analytics, Epidemiological Studies, Deals Analytics, Patent Analytics of Pipeline Drugs, Pipeline Drug Descriptions and Development Milestones, Clinical Trial Analytics, Competitive Landscape and Opportunity Assessments and Emerging Company Profiles.

Pipeline Analytics Outlook:

Report summarize the comparative snapshots of all pipeline drugs as per the segments like stages of development, Geography, Route of Administration, Drug Class, Mechanism of Action, molecule type, target receptors and company types.

Drivers, Restrains, Unmet Needs and Opportunities:

Report offers and provides a deep knowledge on the drivers, restraints and unmet needs and the opportunities derived upon a far-reaching study on the market trends and underlying factors affecting Abuse Deterrents landscape.

Pipeline Analytics:

The section covers all the molecules (drug candidates) in different stages of development (Discovery, Pre-clinical, Phase 1, Phase 2, Phase 3 and Pre-registration). It also offers information about the terminated and discontinued molecules. Analytics have been provided by Geography (covers major regions like the US, EU, Asia); by Route of Administration, by Drug Class and by Mechanism of Action. Report explains pipeline analytics by molecule type, target receptor and pipeline analytics by company type. Report also covers pipeline analytics by Universities and Institutes.

Epidemiological Studies:

Our Senior Analysts for conducting Epidemiological Studies uses expertise and proprietary tools to understand the prevailing factors affecting the Disease population. Based on demographics, prevalent factors, incidence rate trends and many other geographical factors, Senior Analysts predicts the future numbers of the affected population over the forecast period, even suggesting the preventative measures.

Deals Analytics:

The report bestows explicit information about the collaborations and partnering activities and trend in Abuse Deterrents landscape, including details about different deals types like Mergers and Acquisitions, Licensing deals, Partnering deals, Collaboration Agreements, Series Financings, Grants and Fundings, etc occurring between 2010-2020.

Patent Analytics of Pipeline Drugs:

The section even contains a thorough analysis on the intellectual property pertaining to Abuse Deterrents pipeline drugs. Profound analytics have been provided related to the patent issuance and applications, patent expiries, patent extensions, etc to gain a complete knowledge on the new market entries filling up the gaps due to the patent expiries.

Pipeline Drug Descriptions and Development Milestones:

Report provides detailed pipeline drugs descriptions covering all key aspects of the pipeline drugs like intended indications, mechanism of action, route of administration and role in pathophysiological conditions. Report even covers all development milestones of the pipeline drugs right from the early research and development to current stage of development.

Clinical Trial Analytics:

The report is inclusive of all the updated clinical trials information, providing details related to the completed clinical trials, ongoing clinical trials, planned clinical trials, even including complete analytics based on sponsors (companies, universities and institutes) involved in the development of Abuse Deterrents Therapeutics.

Competitive Landscape and Opportunity Assessments:

The report is an absolute package covering all the companies - Established and emerging companies (Clinical-stage companies, pre-clinical stage companies, startups) actively involved in the R&D of new therapeutics for the treatment of Abuse Deterrents. Report provided opportunity assessments by performing a competitive and comparative analysis on the top 20 Emerging companies in the competitive space.

Emerging Company Profiles:

Report features company profiles with data concentrated on: Partnering activities and patent analysis of the company, R&D efforts and advancements, Comparison of internal investment and external funding, Achievements of special regulatory allowances and Outline of in-licensing/out licensing opportunities.

Table of Contents
for Abuse Deterrents: Pipeline Analytics, H1 2020

  • CHAPTER 01: INTRODUCTION

    1.1. REPORT DESCRIPTION

    1.2. METHODOLOGY

    1.3. ABOUT US: GERVANORA DATA SERVICES

    CHAPTER 02: EXECUTIVE SUMMARY

    2.1. REPORT SUMMARY

    2.2. KEY EVENTS IN THE ABUSE DETERRENTS COMPETITIVE SPACE

    2.3. REPORT MAJOR FINDINGS

    2.3.1. DRIVERS

    2.3.2. RESTRAINTS

    2.3.3. OPPORTUNITIES

    CHAPTER 03: PIPELINE ANALYTICS OUTLOOK

    3.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS

    3.1.1. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY STAGE OF DEVELOPMENT

    3.1.2. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY GEOGRAPHY

    3.1.3. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY ROUTE OF ADMINISTRATION

    3.1.4. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY DRUG CLASS

    3.1.5. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MECHANISM OF ACTION

    3.1.6. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULE TYPE

    3.1.7. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY MOLECULAR TARGET

    3.1.8. PIPELINE ANALYTICS COMPARATIVE SNAPSHOTS BY COMPANY TYPE

    3.2. UNMET NEEDS AND MARKET DEMANDS

    3.2.1. UNMET NEEDS AND MARKET DEMANDS FOR NEWER THERAPIES

    3.2.2. UNMET NEEDS AND MARKET DEMANDS BY ROUTE OF ADMINISTRATION

    3.2.3. UNMET NEEDS AND MARKET DEMANDS BY GEOGRAPHY

    3.3 MARKET DYNAMICS OF ABUSE DETERRENTS COMPETITIVE LANDSCAPE

    CHAPTER 04: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

    4.1. DISEASE DEFINITION AND SYMPTOMS

    4.2. DISEASE CAUSE AND PATHOPHYSIOLOGY

    4.3. DISEASE DIAGNOSIS

    4.4. TREATMENT ALGORITHM AND GUIDELINES

    4.5. EPIDEMIOLOGY STUDIES

    3.5.1. GLOBAL AND HISTORICAL TRENDS

    4.6. EPIDEMIOLOGY FORECAST

    4.6.1. FORECAST METHODOLOGY AND ASSUMPTIONS

    4.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST

    CHAPTER 05: DEALS (M&A) ANALYTICS OF ABUSE DETERRENTS COMPETITIVE LANDSCAPE

    4.1. DEALS (MERGERS/ ACQUISITIONS/ COLLABORATIONS)

    4.1.1 DEALS ANALYTICS BY DEAL TYPE

    4.1.1.1. COLLABORATION DEALS

    4.1.1.2. LICENSING DEALS

    4.1.1.3. FINANCING DEALS

    4.1.2 DEALS ANALYTICS BY ANNUAL FREQUENCY

    4.1.3 DEALS ANALYTICS BY ACTIVE PLAYER

    CHAPTER 06: PATENT ANALYTICS OF ABUSE DETERRENTS PIPELINE DRUGS

    6.1. PATENT ANALYTICS BY GEOGRAPY

    6.2. PATENT ANALYTICS BY PATENT EXPIRY

    6.3. PATET ANALYTICS BY SPECIAL ALLOWANCES AND TERM EXTENSIONS

    CHAPTER 07: PIPELINE DRUGS ANALYTICS OF ABUSE DETERRENTS

    7.1. PIPELINE DRUGS ANALYTICS BY STAGE OF DEVELOPMENT

    5.1.1. PRE-REGISTRATION PIPELINE DRUGS

    5.1.2. PHASE III PIPELINE DRUGS

    5.1.3. PHASE II PIPELINE DRUGS

    5.1.4. PHASE I/II PIPELINE DRUGS

    5.1.5. PHASE I PIPELINE DRUGS

    5.1.6. PRE-CLINICAL PIPELINE DRUGS

    5.1.7. EARLY R&D PIPELINE DRUGS

    5.1.8. INACTIVE AND DISCONTINOUED PIPELINE DRUGS

    5.2. PIPELINE DRUGS ANALYTICS BY GEOGRAPHY

    5.3. PIPELINE DRUGS ANALYTICS BY ROUTE OF ADMINISTRATION

    5.4. PIPELINE DRUGS ANALYTICS BY DRUG CLASS

    5.5. PIPELINE DRUGS ANALYTICS BY MECHANISM OF ACTION

    5.6. PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE

    5.7. PIPELINE DRUGS ANALYTICS BY TARGET RECEPTORS

    5.8. PIPELINE DRUGS ANALYTICS BY COMPANY TYPE

    CHAPTER 08: PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.1. PRE-REGISTRATION PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.2. PHASE III PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.3. PHASE II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.4. PHASE I/II PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    6.5. PHASE I PIPELINE DRUGS DESCRIPTIONS AND DEVELOPMENT MILESTONES

    CHAPTER 09: ESTIMATED APPROVAL TIMELINES OF ABUSE DETERRENTS PIPELINE DRUGS

    7.1. METHODOLOGY

    7.2. ESTIMATED APPROVAL TIMELINES US & EX-US

    CHAPTER 10: OPPORTUNITY ASSESSMENTS THROUGH COMPETITIVE BENCH-MARKING

    8.1. EXTERNAL DEPENDENCIES

    8.1.1. BUSINESS R&D - INTERNAL INVESTMENT AND EXTERNAL FUNDING

    8.2. PIPELINE PORTFOLIO

    8.3. EXPECTED MARKET ENTRIES

    8.4. PATENTS AND EXCLUSIVITY

    8.5. MARKET DYNAMICS AND PARTNERING

    8.6. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCES

    8.7. COMPANY DEVELOPMENTS

    CHAPTER 11: CURRENT AND FUTURE COMPETITIVE LANDSCAPE

    9.1. EMERGING COMPANIES

    9.1.1 EMERGING COMPANY PROFILES

List Of Tables
in Abuse Deterrents: Pipeline Analytics, H1 2020

LIST OF TABLES

• TABLE 01: ABUSE DETERRENTS REPORT HIGHLIGHTS IN NUMERICALS

• TABLE 02: ABUSE DETERRENTS AFFECTED POPULATION GLOBALLY

• TABLE 03: COLLABORATION DEALS IN ABUSE DETERRENTS THERAPEUTIC AREA

• TABLE 04: LICENSING DEALS IN ABUSE DETERRENTS THERAPEUTIC AREA

• TABLE 05: FINANCING DEALS IN ABUSE DETERRENTS THERAPEUTIC AREA

• TABLE 6: ABUSE DETERRENTS PHASE III PIPELINE MOLECULES

• TABLE 7: ABUSE DETERRENTS PHASE II PIPELINE MOLECULES

• TABLE 8: ABUSE DETERRENTS PHASE I/II PIPELINE MOLECULES

• TABLE 9: ABUSE DETERRENTS PHASE I PIPELINE MOLECULES

• TABLE 10: PRECLINICAL STAGE DRUG CANDIDATES FOR ABUSE DETERRENTS

• TABLE 11: LIST OF PIPELINE MOLECULES OF PARENTERAL ROUTE OF ADMINISTRATION

• TABLE 12: LIST OF PIPELINE MOLECULES OF ORAL ROUTE OF ADMINISTRATION

• (Remaining Tables can be seen in detailed Report)

List Of Figures, Charts and Diagrams
in Abuse Deterrents: Pipeline Analytics, H1 2020

LIST OF FIGURES

• FIGURE 01: KEY EVENTS IN THE ABUSE DETERRENTS COMPETITIVE SPACE

• FIGURE 02: ABUSE DETERRENTS DEAL ANALYTICS BY DEAL TYPE

• FIGURE 03: ABUSE DETERRENTS DEAL ANALYTICS BY DEAL FREQUENCY

• FIGURE 04: PIPELINE MOLECULES - CLINICAL VS PRECLINICAL & EARLY R&D

• FIGURE 05: TOTAL PIPELINE MOLECULES VS STAGE OF DEVELOPMENT

• FIGURE 06: ABUSE DETERRENTS DRUGS PIPELINE ANALYTICS BY ROA

• FIGURE 07: ABUSE DETERRENTS DRUGS PIPELINE ANALYTICS BY PARENTERAL ROA

• FIGURE 08: PARENTERAL DRUGS PIPELINE ANALYTICS BY HSD

• FIGURE 09: ORAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT

• FIGURE 10: TOTAL PIPELINE MOLECULES V/S DRUG CLASSES

• FIGURE 11: PIPELINE DRUG CLASS ANALYTICS BY STAGE OF DEVELOPMENT

• FIGURE 12: ABUSE DETERRENTS PIPELINE DRUGS BIOLOGICALS VS SMALL MOLECULES

• FIGURE 13: ABUSE DETERRENTS PIPELINE DRUGS ANALYTICS BY MOLECULE TYPE VS STAGE OF DEVELOPMENT

• FIGURE 14: ABUSE DETERRENTS COMPANIES (NUMBER, PERCENT SHARE)

• FIGURE 15: GEOGRAPHICAL CATEGORIZATION OF COMPANIES WORKING ON ABUSE DETERRENTS

• (Remaining Figures can be seen in detailed Report)

Additional Details

Publisher

Gervano R A

Publisher Information

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.



GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.



At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Reference

270539 | GERPH507

Number of Pages

188

Report Format

PDF

Gervano R A Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Residential Substance Abuse and Mental Health Facilities Global Market Briefing 2016 Including: Mental Health And Substance Abuse Centers and Residential Intellectual Disability Facilities Historic and Forecast Growth Rate 2011 – 2019 Covering: Asia, Europe, Americas, Middle East & Africa, Oceania
Substance Abuse and Residential Mental Health Facilities Global Market Briefing provides strategists...
05 Dec 2016 by The Business Research Company USD $1,000 More Info
Residential Substance Abuse and Mental Health Facilities Global Market Briefing 2017 Including: Mental Health And Substance Abuse Centers and Residential Intellectual Disability Facilities
Residential substance abuse and mental health facilities provide medical services, room, board, supe...
18 Nov 2016 by The Business Research Company USD $750 More Info
Healthcare Services Global Market Briefing 2017 Including: Hospitals And Outpatient Care Centers, Physicians And Other Healthcare Practitioners, Home Healthcare And Residential Nursing Care Services, Medical And Diagnostic Laboratories, Dental Services, Substance Abuse And Residential Mental Health, Veterinary Services
Healthcare services deal with medical and remedial care service. Healthcare services also include fu...
18 Nov 2016 by The Business Research Company USD $750 More Info
PAIN MANAGEMENT- NEW DISCOVERIES AND TREATMENT OPTIONS IN ABUSE DETERRENT ERA • Opioids - Novel Abuse deterrent Formulation Technologies & Pipeline drugs • Emerging Novel Technologies, Mechanisms and late stage pipeline drugs in the Management of Pain
Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline ...
01 Sep 2016 by MP Advisors USD $7,000 More Info
Residential Substance Abuse and Mental Health Facilities Global Market Analytics Report 2016 Including: Mental Health And Substance Abuse Centers and Residential Intellectual Disability Facilities Analysing: Expenditure Per Capita, Expenditure Per Household, Government Expenditure, Healthcare Indicators Comparison, Surgical Procedures Historic and Forecast Growth Rate 2011 – 2019 Covering: Asia,
The Residential Substance Abuse and Mental Health Facilities Market Analytics Report provides strate...
23 May 2016 by The Business Research Company USD $2,000 More Info
National Institute on Drug Abuse - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryNational Institute on Drug Abuse (NIDA), a subsidiary of National Institutes of Health is a r...
27 Apr 2016 by Global Data USD $250 More Info
Substance Abuse Deterrents and Treatments - An Assessment of the Technological, Competitive and R&D Landscape
Substance Abuse Deterrents and Treatments - An Assessment of the Technological, Competitive and R&D ...
16 Mar 2016 by CBR Pharma Insights USD $2,995 More Info
Substance Abuse Deterrents and Treatments - An Assessment of the Technological, Competitive and R&D Landscape
Substance Abuse Deterrents and Treatments - An Assessment of the Technological, Competitive and R&D ...
16 Mar 2016 by CBR Pharma Insights USD $2,995 More Info
National Institute on Drug Abuse - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryNational Institute on Drug Abuse (NIDA), a subsidiary of National Institutes of Health is a r...
14 Mar 2016 by Global Data USD $250 More Info
Physician Views: As FDA becomes more constructive on regulation what is the physician perception towards abuse deterrent opioids?
ScopeIn the US, the misuse and abuse of opioid medications has triggered significant industry invest...
01 Jun 2015 by FirstWord Pharma USD $695 More Info

This report is published by Gervano R A

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.

GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.

At GervanoRA Data Services, we’re playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

Download Free Report Summary PDF

Abuse Deterrents: Pipeline Analytics, H1 2020 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...